argenx SE is a biopharmaceutical company that discovers and develops immunoglobulin Fc-mediated therapies for severe autoimmune diseases and neuromuscular conditions. The company's lead approved product is VYVGART, a first-in-class IgG Fc-antibody fragment that reduces pathogenic antibodies and is available in multiple formulations for indications including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and immune thrombocytopenia. argenx generates revenue primarily through product net sales of VYVGART and out-license agreements in territories such as Greater China, while investing substantially in a pipeline of next-generation therapies targeting complement pathways, muscle-specific kinase, and other immunology targets, supported by proprietary discovery platforms leveraging llama antibody technology and Fc-region engineering capabilities.